Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5–10% and >10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several European registries have since validated the ESC/ERS risk status model; however, it is unknown if the ESC/ERS tool predicts clinical worsening or hospitalizations.(288)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [288]
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationMacitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationSelexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Self-citationBenza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R. P., Foreman, A. J., Badesch, D. B., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-0676 · Cited by 557
Kylhammar, D., Kjellström, B., Hjalmarsson, C., Jansson, K., Nisell, M., Söderberg, S., Wikström, G., & Rådegran, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx257 · Cited by 540
Hoeper, M. M., Huscher, D., Ghofrani, H. A., Delcroix, M., Distler, O., Schweiger, C., Grunig, E., Staehler, G., Rosenkranz, S., Halank, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.026 · Cited by 466
Self-citationUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Cited by
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Self-citationLeard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
“288 Finally, this approach, similar to the RSS, still needs to be validated prospectively.”
MethodRisk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Self-citationPulmonary Arterial Hypertension
Hassoun, P. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2000348 · Cited by 693
Predicting Survival in Patients With Pulmonary Arterial Hypertension
Benza, R. L., Gomberg-Maitland, M., Elliott, C. G., Farber, H. W., Foreman, A. J., Frost, A. E., McGoon, M. D., Pasta, D. J., Selej, M., Burger, C. D., et al. (2019) · Chest · doi:10.1016/j.chest.2019.02.004 · Cited by 643
“1%.(22) Applying the FPHR strategy,(23) this patient would be characterized as having no low-risk criteria, which corresponds to a 12-month survival of approximately 94%.”
BackgroundMethodRosenzweig, E. B., Abman, S. H., Adatia, I., Beghetti, M., Bonnet, D., Haworth, S., Ivy, D. D., & Berger, R. M. F. (2019) · European Respiratory Journal · doi:10.1183/13993003.01916-2018 · Cited by 628
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
Hoeper, M. M., Pausch, C., Olsson, K. M., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., Gall, H., Distler, O., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02311-2021 · Cited by 349
“According to current guidelines, achieving and maintaining a low risk profile is a major treatment objective in PAH [1-3], but it has been shown that this goal is not reached in most patients [4, 6, 20].”
InfluentialSelf-citationBenza, R. L., Kanwar, M. K., Raina, A., Scott, J. V., Zhao, C. L., Selej, M., Elliott, C. G., & Farber, H. W. (2021) · Chest · doi:10.1016/j.chest.2020.08.2069 · Cited by 341
Augustine, D. X., Coates-Bradshaw, L. D., Willis, J., Harkness, A., Ring, L., Grapsa, J., Coghlan, G., Kaye, N., Oxborough, D., Robinson, S., et al. (2018) · Echo Research & Practice · doi:10.1530/erp-17-0071 · Cited by 333
Pulmonary Hypertension: A Brief Guide for Clinicians
Mandras, S. A., Mehta, H. S., & Vaidya, A. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.04.039 · Cited by 271
Treatment algorithm for pulmonary arterial hypertension
Chin, K. M., Gaine, S. P., Gerges, C., Jing, Z.-C., Mathai, S. C., Tamura, Y., McLaughlin, V. V., & Sitbon, O. (2024) · European Respiratory Journal · doi:10.1183/13993003.01325-2024 · Cited by 252
“…from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL registry), including REVEAL 2.0 and REVEAL lite 2.0 [41], and the European Society of Cardiology (ESC)/European Respiratory Society (ERS) calculator, studied with slight variations across multiple cohorts [42 – 46].”
BackgroundInfluentialChang, K. Y., Duval, S., Badesch, D. B., Bull, T. M., Chakinala, M. M., De Marco, T., Frantz, R. P., Hemnes, A., Mathai, S. C., Rosenzweig, E. B., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024969 · Cited by 236
Hoeper, M. M., Pausch, C., Grünig, E., Klose, H., Staehler, G., Huscher, D., Pittrow, D., Olsson, K. M., Vizza, C. D., Gall, H., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.09.011 · Cited by 217
“PAH medication within 3 months after diagnosis Calcium channel blocker monotherapy, n (%) 16 (16) 3 (1) 5 (1) 24 (3) PDE5i or sGC stimulators, n (%) 76 (76) 257 (90) 358 (86) 691 (86) ERA, n (%) 43 (43) 59 (21) 108 (26) 210 (26) PCA, n (%) 5 (5) 7 (2) 6 (1) 18 (2) Combination therapies, n (%) 38 (38) 38 (13) 63 (15) 1…”
Self-citationHoeper, M. M., Benza, R. L., Corris, P., de Perrot, M., Fadel, E., Keogh, A. M., Kühn, C., Savale, L., & Klepetko, W. (2019) · European Respiratory Journal · doi:10.1183/13993003.01906-2018 · Cited by 216
Self-citationBoucly, A., Weatherald, J., Savale, L., de Groote, P., Cottin, V., Prévot, G., Chaouat, A., Picard, F., Horeau-Langlard, D., Bourdin, A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02419-2021 · Cited by 207
Boucly, A., Savale, L., Jaïs, X., Bauer, F., Bergot, E., Bertoletti, L., Beurnier, A., Bourdin, A., Bouvaist, H., Bulifon, S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202009-3698oc · Cited by 204
Clinical trial design and new therapies for pulmonary arterial hypertension
Sitbon, O., Gomberg-Maitland, M., Granton, J., Lewis, M. I., Mathai, S. C., Rainisio, M., Stockbridge, N. L., Wilkins, M. R., Zamanian, R. T., & Rubin, L. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.01908-2018 · Cited by 196
Phosphodiesterase 5 inhibitors for pulmonary hypertension
Barnes, H., Brown, Z., Burns, A., & Williams, T. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012621.pub2 · Cited by 196
Pulmonary Hypertension: A Contemporary Review
Johnson, S., Sommer, N., Cox-Flaherty, K., Weissmann, N., Ventetuolo, C. E., & Maron, B. A. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202302-0327so · Cited by 190
Pathophysiology and new advances in pulmonary hypertension
Bousseau, S., Fais, R. S., Gu, S., Frump, A. L., & Lahm, T. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000137 · Cited by 188
Portopulmonary hypertension in the current era of pulmonary hypertension management
Savale, L., Guimas, M., Ebstein, N., Fertin, M., Jevnikar, M., Renard, S., Horeau-Langlard, D., Tromeur, C., Chabanne, C., Prevot, G., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.021 · Cited by 170
Lewis, R. A., Johns, C., Cogliano, M., Capener, D. A., Tubman, E., Elliot, C. A., Charalampopoulos, A. F., Sabroe, I., Thompson, A. A. R., Billings, C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1771oc · Cited by 169
“A number of registry studies have shown that in patients whose risk profile can be modified to low risk, outcomes are significantly improved (13, 15).”
BackgroundResultD’Alto, M., Badagliacca, R., Argiento, P., Romeo, E., Farro, A., Papa, S., Sarubbi, B., Russo, M. G., Vizza, C. D., Golino, P., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.09.009 · Cited by 167
Self-citationRisk stratification and treatment goals in pulmonary arterial hypertension
Dardi, F., Boucly, A., Benza, R. L., Frantz, R. P., Mercurio, V., Olschewski, H., Rådegran, G., Rubin, L. J., & Hoeper, M. M. (2024) · European Respiratory Journal · doi:10.1183/13993003.01323-2024 · Cited by 165
“However, the latter were available in no more than one-third of patients at follow-up [123, 134].”
InfluentialSelf-citationHoeper, M. M., Al-Hiti, H., Benza, R. L., Chang, S.-A., Corris, P. A., Gibbs, J. S. R., Grünig, E., Jansa, P., Klinger, J. R., Langleben, D., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30532-4 · Cited by 159
Self-citationImpact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension
Hjalmarsson, C., Rådegran, G., Kylhammar, D., Rundqvist, B., Multing, J., Nisell, M., & Kjellström, B. (2018) · European Respiratory Journal · doi:10.1183/13993003.02310-2017 · Cited by 147
“These results, as well as those from the COMPERA study [10], are in accordance with our findings, suggesting that our patient population is highly representative of the IPAH population, according to the present definition.”
BackgroundInfluentialGermlineBMP9mutation causes idiopathic pulmonary arterial hypertension
Wang, X., Lian, T., Jiang, X., Liu, S., Li, S.-Q., Jiang, R., Wu, W., Ye, J., Cheng, C., Du, Y., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01609-2018 · Cited by 147
Rajagopal, S., Ruetzler, K., Ghadimi, K., Horn, E. M., Kelava, M., Kudelko, K. T., Moreno‐Duarte, I., Preston, I. R., Bovino, L. R., Smilowitz, N. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001136 · Cited by 147
BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
Lewis, R. A., Durrington, C., Condliffe, R. A., & Kiely, D. G. (2020) · European Respiratory Review · doi:10.1183/16000617.0009-2020 · Cited by 134
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
Souza, R., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg‐Maitland, M., McLaughlin, V. V., Preston, I. R., Waxman, A. B., Grünig, E., Kopeć, G., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.01107-2023 · Cited by 134
Self-citationPrice, L., Martinez, G. C., Brame, A., Pickworth, T., Samaranayake, C. B., Alexander, D. J., Garfield, B. E., Aw, T., McCabe, C., Mukherjee, B., et al. (2021) · British Journal of Anaesthesia · doi:10.1016/j.bja.2021.01.005 · Cited by 126
Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany
Kramm, T., Wilkens, H., Fuge, J., Schäfers, H., Guth, S., Wiedenroth, C. B., Weingard, B., Huscher, D., Pittrow, D., Cebotari, S., et al. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1215-5 · Cited by 123
“COMPERA is the official German PH registry and has broad participation from German PH centres [22].”
BackgroundSelf-citationEvaluation and management of pulmonary arterial hypertension
Beshay, S. M., Sahay, S., & Humbert, M. J. C. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106099 · Cited by 123
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Humbert, M. J. C., Farber, H. W., Ghofrani, H. A., Benza, R. L., Busse, D., Meier, C., & Hoeper, M. M. (2019) · European Respiratory Journal · doi:10.1183/13993003.02004-2018 · Cited by 120
“other strata, at both baseline and follow-up [13-15].”
Self-citationPulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
McLaughlin, V. V., Hoeper, M. M., Channick, R. N., Chin, K., Delcroix, M., Gaine, S., Ghofrani, H. A., Jansa, P., Lang, I. M., Mehta, S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.010 · Cited by 118
Self-citationChin, K., Rubin, L. J., Channick, R. N., Scala, L. D., Gaine, S., Galiè, N., Ghofrani, H. A., Hoeper, M. M., Lang, I. M., McLaughlin, V. V., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039360 · Cited by 108
Self-citationScreening for pulmonary arterial hypertension in systemic sclerosis
Weatherald, J. C., Montani, D., Jevnikar, M., Jaïs, X., Savale, L., & Humbert, M. J. C. (2019) · European Respiratory Review · doi:10.1183/16000617.0023-2019 · Cited by 104
Risk assessment in pulmonary arterial hypertension
Hoeper, M. M., Pittrow, D., Opitz, C. F., Gibbs, J. S. R., Rosenkranz, S., Grünig, E., Olsson, K. M., & Huscher, D. (2018) · European Respiratory Journal · doi:10.1183/13993003.02606-2017 · Cited by 100
Self-citationWeatherald, J. C., Boucly, A., Launay, D., Cottin, V., Prévôt, G., Bourlier, D., Dauphin, C., Chaouat, A., Savale, L., Jaïs, X., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00678-2018 · Cited by 99
Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients
Delcroix, M., Staehler, G., Gall, H. J., Grünig, E., Held, M., Halank, M., Klose, H. F. E., Noordegraaf, A. V., Rosenkranz, S., Pepke‐Żaba, J., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00248-2018 · Cited by 98
Self-citationPulmonary Arterial Hypertension: a Pharmacotherapeutic Update
Coons, J. C., Pogue, K. T., Kolodziej, A., Hirsch, G. A., & George, M. P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1235-4 · Cited by 98
Rosenkranz, S., Pausch, C., Coghlan, G., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., Gall, H. J., Distler, O., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.003 · Cited by 94
“A limitation of the 3-strata risk model is that the proportion of patients achieving the low-risk category is small while the vast majority are categorized as an intermediate risk both at diagnosis and follow-up.(3,4) Recently, a modified risk stratification tool using a 4-strata model based on refined cut-off levels…”
BackgroundMethodSelf-citationScreening strategies for pulmonary arterial hypertension
Kiely, D. G., Lawrie, A., & Humbert, M. J. C. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz204 · Cited by 91
“Exercise testing There are limited data on the natural history of early pulmonary vascular disease since patients usually present with advanced disease.(7) However, it is generally accepted that the development of exercise-induced PH precedes resting PH.”
BackgroundKopeć, G., Kurzyna, M., Mroczek, E., Chrzanowski, Ł., Mularek‐Kubzdela, T., Skoczylas, I., Kuśmierczyk, B., Pruszczyk, P., Błaszczak, P., Lewicka, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010173 · Cited by 88
Pulmonary arterial hypertension specific therapy: The old and the new
Zolty, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107576 · Cited by 87
Avdeev, S. N., Барбараш, О. Л., Солтановна, В. З., Volkov, A. V., Veselova, T. N., Galyavich, A. S., Goncharova, N. S., Gorbachevsky, S. V., Владимирович, Г. В., Danilov, N. M., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6161 · Cited by 85
Qian, J., Li, M., Zhang, X., Wang, Q., Zhao, J., Tian, Z., Wei, W., Zuo, X., Zhang, M., Zhu, P., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00081-2018 · Cited by 84
“Although the goal-orientated treatment approach has not been fully validated, several studies have shown recently that PAH patients in a “low-risk” group showed a decreased mortality risk [30-32].”
ResultA comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension
Ghio, S., Mercurio, V., Fortuni, F., Forfia, P. R., Gall, H. J., Ghofrani, H. A., Mathai, S. C., Mazurek, J. A., Mukherjee, M., Richter, M. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00513-2020 · Cited by 84
Self-citationHoeper, M. M., Apitz, C., Grünig, E., Halank, M., Ewert, R., Kaemmerer, H. M., Kabitz, H., Kähler, C. M., Klose, H. F. E., Leuchte, H. H., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.08.082 · Cited by 83
Self-citationLeng, S., Dong, Y., Wu, Y. F., Zhao, X., Ruan, W., Zhang, G., Allen, J. C., Koh, A. S.-M., Tan, R., Yip, J., et al. (2019) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.118.008582 · Cited by 82
McGlothlin, D. P., Granton, J. T., Klepetko, W., Beghetti, M., Rosenzweig, E. B., Corris, P. A., Horn, E. M., Kanwar, M. K., McRae, K. M., Román, A., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.06.013 · Cited by 81
Self-citationPulmonary Arterial Hypertension: Combination Therapy in Practice
Burks, M., Stickel, S., & Galiè, N. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0272-5 · Cited by 81
Pulmonary Arterial Hypertension
Dodson, M. W., Brown, L. M., & Elliott, C. G. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.02.003 · Cited by 80
Guignabert, C., Savale, L., Boucly, A., Thuillet, R., Tu, L., Ottaviani, M., Rhodes, C. J., de Groote, P., Prévôt, G., Bergot, E., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061501 · Cited by 80
Benza, R. L., Grünig, E., Sandner, P., Stasch, J., & Simonneau, G. (2024) · European Respiratory Review · doi:10.1183/16000617.0183-2023 · Cited by 80
Self-citationPreston, I. R., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg‐Maitland, M., Hoeper, M. M., Humbert, M. J. C., McLaughlin, V. V., Waxman, A. B., Manimaran, S., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.01435-2024 · Cited by 80
Self-citationKuwana, M., Blair, C. J., Takahashi, T., Langley, J., & Coghlan, G. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216274 · Cited by 79
“11 Another approach to improve risk stratification could be to use the seven-parameter stratification as per the COMPERA analysis 24 for risk stratification at baseline, with the abbreviated four-parameter non-invasive method 23 at follow-up.”
Pulmonary hypertension in connective tissue diseases, new evidence and challenges
Vonk, M. C., Vandecasteele, E. H., & van Dijk, A. P. J. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13453 · Cited by 75
Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment
Fauvel, C., Raitiere, O., Boucly, A., de Groote, P., Renard, S., Bertona, J., Lamblin, N., Artaud-Macari, É., Viacroze, C., Schleifer, D., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.005 · Cited by 75
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
Sitbon, O., Chin, K., Channick, R. N., Benza, R. L., Scala, L. D., Gaine, S., Ghofrani, H. A., Lang, I. M., McLaughlin, V. V., Preiss, R., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.12.013 · Cited by 75
Self-citationKhanna, D., Zhao, C., Saggar, R., Mathai, S. C., Chung, L. S., Coghlan, G., Shah, M., Hartney, J. M., & McLaughlin, V. V. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41669 · Cited by 74
“An additional area of focus should be standardized reporting of baseline risk profiles, since data suggest that patients with CTDPAH are at greater risk of death despite a less severe hemodynamic phenotype (5,55).”
BackgroundThe evolving landscape of pulmonary arterial hypertension clinical trials
Weatherald, J. C., Boucly, A., Peters, A. E., Montani, D., Prasad, K., Psotka, M. A., Zannad, F. M., Gomberg‐Maitland, M., McLaughlin, V. V., Simonneau, G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01601-4 · Cited by 73
Autogenous mitochondria transplantation for treatment of right heart failure
Weixler, V. H.-M., Lapusca, R., Grangl, G., Guariento, A., Saeed, M. Y., Cowan, D. B., del Nido, P. J., McCully, J. D., & Friehs, I. (2020) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2020.08.011 · Cited by 72
Zelt, J. G. E., Sugarman, J. A., Weatherald, J. C., Partridge, A. C. R., Liang, J., Swiston, J. R., Brunner, N. W., Chandy, G., Stewart, D. J., Contreras-Domínguez, V., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.01552-2021 · Cited by 71
Wang, J., Li, M., Wang, Q., Zhang, X., Qian, J., Zhao, J., Xu, D., Tian, Z., Wei, W., Zuo, X., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02157-2019 · Cited by 67
Thomas, C. A., Anderson, R. J., Condon, D. F., & Pérez, V. D. J. (2019) · Pulmonary Therapy · doi:10.1007/s41030-019-00105-5 · Cited by 65
Kramer, T., Dumitrescu, D., Gerhardt, F., Orlova, K., ten Freyhaus, H., Hellmich, M., Baldus, S. E., & Rosenkranz, S. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.078 · Cited by 64
Self-citationMonitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor
Benza, R. L., Doyle, M., Lasorda, D., Parikh, K. S., Correa‐Jaque, P., Badie, N., Ginn, G., Airhart, S. E., Franco, V., Kanwar, M. K., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.06.010 · Cited by 64
Lewis, R. A., Armstrong, I. J., Bergbaum, C., Brewis, M. J., Cannon, J. E., Charalampopoulos, A. F., Church, C., Coghlan, G., Davies, R. J., Dimopoulos, K., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00124-2020 · Cited by 64
“This effect has been seen in a number of other risk stratification parameters and scores (25-27), and the importance of achieving specific PROM thresholds in PAH has also been observed with the generic SF-36 (28).”
BackgroundSelf-citationMalenfant, S., Lebret, M., Breton-Gagnon, É., Potus, F., Paulin, R., Bonnet, S., & Provencher, S. (2021) · European Respiratory Review · doi:10.1183/16000617.0284-2020 · Cited by 62
Kariotis, S., Jammeh, E., Swietlik, E. M., Pickworth, J. A., Rhodes, C. J., Otero, P., Wharton, J., Iremonger, J., Dunning, M., Pandya, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27326-0 · Cited by 62
Self-citationEl‐Kersh, K., Zhao, C., Elliott, G. C., Farber, H. W., Gomberg‐Maitland, M., Selej, M., Garcia‐Ferrer, J., & Benza, R. L. (2023) · CHEST Journal · doi:10.1016/j.chest.2022.12.045 · Cited by 62
Thoreau, B., & Mouthon, L. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103506 · Cited by 62
Avdeev, S. N., Барбараш, О. Л., Баутин, А. Е., Volkov, A. V., Veselova, T. N., Galyavich, A. S., Goncharova, N. S., Gorbachevsky, S. V., Danilov, N. M., Еременко, А. А., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4683 · Cited by 61
Sofianopoulou, E., Kaptoge, S. K., Gräf, S., Hadinnapola, C., Treacy, C., Church, C., Coghlan, G., Gibbs, J. S. R., Haimel, M., Howard, L., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01429-2018 · Cited by 61
Self-citationMacitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
Jansa, P., & Pulido, T. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0260-1 · Cited by 60
“and long-term outcomes than those who do not [16, 30, 42, 43].”
BackgroundLearning from registries in pulmonary arterial hypertension: pitfalls and recommendations
Swinnen, K., Quarck, R. A., Godinas, L., Belge, C., & Delcroix, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0050-2019 · Cited by 60
Self-citationDauriat, G., Reynaud‐Gaubert, M., Cottin, V., Lamia, B., Montani, D., Canuet, M., Boissin, C., Tromeur, C., Chaouat, A., Degano, B., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.021 · Cited by 59
Yogeswaran, A., Kuhnert, S., Gall, H. J., Faber, M., Krauss, E., Rako, Z. A., Keranov, S., Grimminger, F., Ghofrani, H. A., Naeije, R., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.826369 · Cited by 57
Self-citationBadagliacca, R., Papa, S., Matsubara, H., Lang, I. M., Poscia, R., Manzi, G., & Vizza, C. D. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.10.043 · Cited by 56
Self-citationGerhardt, F., Fiessler, E., Olsson, K. M., Kayser, M. Z., Kovács, G., Gall, H. J., Ghofrani, H. A., Eslam, R. B., Lang, I. M., Benjamin, N., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.063821 · Cited by 55
“14,15 For the 4-strata approach, patients were categorized as low risk, intermediate–low risk, intermediate–high risk, or high risk according to cutoff values for WHO-FC, 6MWD, and NT-proBNP only.”
Self-citationWeatherald, J. C., Boucly, A., Sahay, S., Humbert, M. J. C., & Sitbon, O. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1840pp · Cited by 55
“In another recent study, using the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), Hoeper and colleagues included 1,588 patients with PAH from several European countries (80% were German) and categorized patients into risk groups similarly to Kylhammar and colleague…”
Risk stratification in pulmonary arterial hypertension using Bayesian analysis
Kanwar, M. K., Gomberg‐Maitland, M., Hoeper, M. M., Pausch, C., Pittrow, D., Strange, G. A., Anderson, J., Zhao, C., Scott, J. V., Drużdżel, M. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00008-2020 · Cited by 55
Self-citationComparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension
Yogeswaran, A., Gall, H. J., Fünderich, M., Wilkins, M. R., Howard, L., Kiely, D. G., Lawrie, A., Hassoun, P. M., Sirenklo, Y., Torbas, O. O., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.03.018 · Cited by 54
Self-citationHassan, H. J., Naranjo, M., Ayoub, N., Housten, T., Hsu, S., Balasubramanian, A., Simpson, C. E., Damico, R. L., Mathai, S. C., Kolb, T. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202204-0731oc · Cited by 53
Badagliacca, R., Rischard, F. P., Papa, S., Kubba, S., Vanderpool, R. R., Yuan, J. X. ‐., Garcia, J. G. N., Airhart, S. E., Poscia, R., Pezzuto, B., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.12.012 · Cited by 53
Self-citationQuan, R., Zhang, G., Yu, Z., Zhang, C., Yang, Z., Tian, H., Yang, Y., Wu, W., Chen, Y., Liu, Y., et al. (2022) · Respirology · doi:10.1111/resp.14247 · Cited by 52
Pulmonary arterial hypertension: tailoring treatment to risk in the current era
Gaine, S., & McLaughlin, V. V. (2017) · European Respiratory Review · doi:10.1183/16000617.0095-2017 · Cited by 52
Sweatt, A. J., Miyagawa, K., Rhodes, C. J., Taylor, S., del Rosario, P. A., Hsi, A., Haddad, F., Spiekerkoetter, E. F., Roof, M. B., Bland, R. D., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.028 · Cited by 52
“59) 817 (600-1048) 8 (6-12) 55 (47-63) 2.”
Karia, N., Howard, L., Johnson, M., Kiely, D. G., Lordan, J. L., McCabe, C., Pepke‐Żaba, J., Ong, R. C.-Y., Preiß, M., Knight, D. S., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad532 · Cited by 51
Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension
Corbach, N., Berlier, C., Lichtblau, M., Schwarz, E. I., Gautschi, F., Groth, A., Schüpbach, R., Krähenmann, F., Saxer, S., & Ulrich, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.689764 · Cited by 51
“0 risk score (14); ESC/ERJ risk score (risk class of each parameter divided by available parameters) (15, 16).”
BackgroundHendriks, P. M., van de Groep, L. D., Veen, K. M., van Thor, M. C. J., Gunput, S. T. G., Boersma, E. H., Boomars, K. A., Post, M. C., & van den Bosch, A. E. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.006 · Cited by 51
Boucly, A., Beurnier, A., Turquier, S., Jevnikar, M., de Groote, P., Chaouat, A., Cheron, C., Jaïs, X., Picard, F., Prévôt, G., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00197-2024 · Cited by 50
Treatment Barriers in Portopulmonary Hypertension
AbuHalimeh, B. J., Krowka, M. J., & Tonelli, A. R. (2018) · Hepatology · doi:10.1002/hep.30197 · Cited by 50
“(32-34) However, one registry(33) excluded patients with PoPH, and the other two(32,34) included a limited number of patients with this condition (2.”
BackgroundLeuchte, H. H., ten Freyhaus, H., Gall, H. J., Halank, M., Hoeper, M. M., Kaemmerer, H. M., Kähler, C. M., Riemekasten, G., Ulrich, S., Schwaiblmair, M., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.08.084 · Cited by 50
Self-citationPredicting mortality during long-term follow-up in pulmonary arterial hypertension
Kylhammar, D., Hjalmarsson, C., Hesselstrand, R., Jansson, K., Kavianipour, M., Kjellström, B., Nisell, M., Söderberg, S., & Rådegran, G. (2021) · ERJ Open Research · doi:10.1183/23120541.00837-2020 · Cited by 50
Atualização no Tratamento da Hipertensão Arterial Pulmonar
Fernandes, C. J. C. D. S., Calderaro, D., Assad, A. P. L., Salibe-Filho, W., Morinaga, L. T. K., Hoette, S., Piloto, B. M., Castro, M. A., Lisboa, R. P., da Silva, T. A. F., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200702 · Cited by 50
Inflammasomes: a novel therapeutic target in pulmonary hypertension?
Scott, T., Kemp‐Harper, B. K., & Hobbs, A. J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14375 · Cited by 48
“Associatedmorbidity andmortality are unacceptably high, with 5-year survival standing at almost 50% (Humbert et al., 2010; Benza et al., 2012; Ling et al., 2012; Hoeper et al., 2017).”
BackgroundHirani, N., Brunner, N. W., Kapasi, A., Chandy, G., Rudski, L., Paterson, D. I., Langleben, D., Mehta, S., & Mielniczuk, L. M. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.11.041 · Cited by 48
Metadata
- Authors
- Hoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., Distler, O., Opitz, C., Gibbs, J. S. R., Delcroix, M., Ghofrani, H. A., Huscher, D., Pittrow, D., Rosenkranz, S., & Grünig, E.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Cologne (DE)
- University Hospital Heidelberg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Sapienza University of Rome (IT)
- University Hospital Zurich (CH)
- DRK Kliniken Berlin (DE)
- Imperial College London (GB)
- Universitair Ziekenhuis Leuven (BE)
- Justus-Liebig-Universität Gießen (DE)
- Technische Universität Dresden (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1700740
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2743897368
- Cited by
- 660
- References
- 21
- Citations by year
- 2026: 21 · 2025: 52 · 2024: 74 · 2023: 84 · 2022: 101 · 2021: 111 · 2020: 92 · 2019: 63 · 2018: 53 · 2017: 8
- FWCI
- 48.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- GlaxoSmithKline
- German Centre of Lung Research
- Bayer
- Actelion Pharmaceuticals
- Deutsche Forschungsgemeinschaft (HO 1599/2-1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, mortality prediction, risk stratification, one-year mortality, functional class, 6-minute walk distance, brain natriuretic peptide, right atrial pressure, cardiac index, mixed venous oxygen saturation
- MeSH terms
- Walk Test, Adult, Aged, Aged, 80 and over, Europe, Female, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prospective Studies, Registries, Severity of Illness Index, Practice Guidelines as Topic, Risk Assessment, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.